TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

A protein called TIGIT has become one of the hottest new targets in cancer research. Setbacks in some studies have raised the stakes for the field.

TIGIT Inhibitors In Clinical Trials Emerging As Immune Checkpoint Based Targeted Therapy For Cancer Says Kuick ResearchDelhi, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Global TIGIT Inhibitor Drug ...

UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors ...

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving ...

Just two weeks after dropping a TIGIT candidate jointly developed with GSK, iTeos has announced plans to wind down operations and explore strategic alternatives. The first half of this year has ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting ...

Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study Published Dec 19, 2022 5:00pm EST ...